Galmed pharmaceuticals ltd. (GLMD)
CashFlow / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flow from operating activities
Net loss

-12,299

-16,953

-10,622

-9,103

-17,485

-3,149

Adjustments required to reconcile net loss to net cash used in operating activities
Depreciation and amortization

239

169

50

9

4

5

Linked difference of marketable securities

167

0

0

-

-

-

Stock-based compensation expense

1,394

1,628

970

601

10,851

208

Capital loss

-

-

-

-

10

0

Non-cash financial expenses due to convertible notes modification

-

-

-

-

2,878

0

Amortization of discount/premium on marketable securities

21

44

92

0

0

-

Loss from Realization of marketable securities

-143

-231

-50

0

0

-

Changes in operating assets and liabilities:
Decrease (increase) in other accounts receivable

-129

-95

214

149

2

11

Increase (decrease) in trade payables

-846

863

1,384

-480

954

-89

Increase (decrease) in other accounts payable

671

81

39

-91

228

-103

Decrease in related party

-267

90

-223

-28

38

60

Decrease in deferred revenue

-1,085

1,623

0

0

-

-

Net cash used in operating activities

-12,067

-12,129

-8,474

-

-

-

Cash flow from investing activities
Net cash used in operating activities

-

-

-

-9,241

-2,524

-3,079

Purchase of property and equipment

12

17

159

770

13

32

Proceeds from sale of property and equipment

0

13

0

0

16

0

Investment in available for sale securities

3,869

7,615

26,541

2,246

0

0

Consideration from sale of available for sale securities

10,325

13,955

9,594

0

0

-

Disposal of short-term deposit

0

0

-6,000

6,000

0

-

Net cash provided in (used in) investing activities

6,444

6,336

-11,106

-

-

-

Cash flow from financing activities
Investment in short-term deposit

-

-

-

-

-

0

Net cash provided in (used in) investing activities

-

-

-

-9,016

3

-32

Credit from bank

-

-

-

-

-

9

Receipt of short term loan from bank

-

-

-

-

-

26

Repayments of short-term loan from bank

-

-

-

-

20

6

Receipt of convertible notes

-

-

-

-

1,840

0

Issuance of ordinary shares

15,017

4,479

0

2,000

120

0

Issuance of ordinary shares upon IPO, net

-

-

-

39,856

0

0

Issuance of stock offerings, net of issuance costs

-

-

-

0

-

-

Proceeds from exercise of options

530

255

0

0

-

-

Net cash provided in financing activities

15,547

4,734

0

-

-

-

Issuance of capital note

-

-

-

-

-

3,672

Net cash used in financing activities

-

-

-

41,856

1,940

3,683

Decrease in cash and cash equivalents

9,924

-1,059

-19,580

23,599

-581

572

Supplemental disclosure of cash flow information:
Cash received from interest

202

382

473

0

0

-

Cash paid for taxes

0

106

0

-

-

-

Cash paid for taxes

-

-

-

1

-

0